2020
Exome sequencing implicates genetic disruption of prenatal neuro-gliogenesis in sporadic congenital hydrocephalus
Jin SC, Dong W, Kundishora AJ, Panchagnula S, Moreno-De-Luca A, Furey CG, Allocco AA, Walker RL, Nelson-Williams C, Smith H, Dunbar A, Conine S, Lu Q, Zeng X, Sierant MC, Knight JR, Sullivan W, Duy PQ, DeSpenza T, Reeves BC, Karimy JK, Marlier A, Castaldi C, Tikhonova IR, Li B, Peña HP, Broach JR, Kabachelor EM, Ssenyonga P, Hehnly C, Ge L, Keren B, Timberlake AT, Goto J, Mangano FT, Johnston JM, Butler WE, Warf BC, Smith ER, Schiff SJ, Limbrick DD, Heuer G, Jackson EM, Iskandar BJ, Mane S, Haider S, Guclu B, Bayri Y, Sahin Y, Duncan CC, Apuzzo MLJ, DiLuna ML, Hoffman EJ, Sestan N, Ment LR, Alper SL, Bilguvar K, Geschwind DH, Günel M, Lifton RP, Kahle KT. Exome sequencing implicates genetic disruption of prenatal neuro-gliogenesis in sporadic congenital hydrocephalus. Nature Medicine 2020, 26: 1754-1765. PMID: 33077954, PMCID: PMC7871900, DOI: 10.1038/s41591-020-1090-2.Peer-Reviewed Original ResearchConceptsCongenital hydrocephalusPoor neurodevelopmental outcomesPost-surgical patientsCerebrospinal fluid accumulationNeural stem cell biologyGenetic disruptionWhole-exome sequencingPrimary pathomechanismEarly brain developmentNeurodevelopmental outcomesHigh morbidityCSF diversionMutation burdenFluid accumulationBrain ventriclesCH casesBrain developmentDe novo mutationsPatientsExome sequencingCSF dynamicsDisease mechanismsHydrocephalusNovo mutationsCell types
2000
Outcome of Children in the Indomethacin Intraventricular Hemorrhage Prevention Trial
Ment L, Vohr B, Allan W, Westerveld M, Sparrow S, Schneider K, Katz K, Duncan C, Makuch R. Outcome of Children in the Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics 2000, 105: 485-491. PMID: 10699097, DOI: 10.1542/peds.105.3.485.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalBrain Damage, ChronicCerebral HemorrhageCerebral VentriclesChild, PreschoolDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansIndomethacinInfantInfant, NewbornInfant, Premature, DiseasesMaleNeurologic ExaminationNeuropsychological TestsPregnancyConceptsLow-dose indomethacinIntraventricular hemorrhagePlacebo childrenIndomethacin therapyPreterm infantsEarly administrationNeurologic examinationPrevention trialsLow birth weight preterm infantsStudy childrenBirth weight preterm infantsSeverity of IVHLow birth weight survivorsMean gestational ageWeight preterm infantsAdverse neurodevelopmental outcomesOutcome of childrenStandard neurologic examinationYears of ageNeurodevelopmental handicapPreterm neonatesNeurodevelopmental examinationNeurodevelopmental outcomesCerebral palsyGestational age
1996
Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial.
Ment L, Vohr B, Oh W, Scott D, Allan W, Westerveld M, Duncan C, Ehrenkranz R, Katz K, Schneider K, Makuch R. Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics 1996, 98: 714-8. PMID: 8885951, DOI: 10.1542/peds.98.4.714.Peer-Reviewed Original ResearchMeSH KeywordsCerebral HemorrhageChi-Square DistributionChild DevelopmentChild, PreschoolCyclooxygenase InhibitorsHumansIndomethacinInfantInfant, NewbornInfant, PrematureInfant, Premature, DiseasesInfant, Very Low Birth WeightIntelligence TestsNeurologic ExaminationUltrasonography, Doppler, TranscranialConceptsLow-dose indomethacinMonths' corrected ageIntraventricular hemorrhageCorrected ageNeurodevelopmental followLong-term neurodevelopmental followLow birth weight infantsLow birth weight neonatesBirth weight infantsMean gestational ageBirth weight neonatesStandard neurologic examinationAdverse cognitive outcomesIncidence of deafnessDose indomethacinWeight infantsPreterm infantsProspective trialWeight neonatesCranial ultrasoundEarly administrationNeurodevelopmental outcomesNeurologic examinationCerebral palsyGestational age
1985
Early Childhood Developmental Follow-Up of Infants with GMH/IVH: Effect of Methylxanthine Therapy
Ment L, Scott D, Ehrenkranz R, Duncan C. Early Childhood Developmental Follow-Up of Infants with GMH/IVH: Effect of Methylxanthine Therapy. American Journal Of Perinatology 1985, 2: 223-227. PMID: 4015773, DOI: 10.1055/s-2007-999955.Peer-Reviewed Original ResearchConceptsGMH/IVHMethylxanthine therapyCerebral blood flowBlood flowSmall preterm neonatesBayley mental scoresIdiopathic apneaBirthweight neonatesPreterm neonatesIntraventricular hemorrhageNeurodevelopmental outcomesNeonatal periodMental scoresGerminal matrixTherapyIVHUnderlying disturbanceInfantsAdverse effectsFurther studiesNeonatesCognitive functioningHarmful effectsMetabolismApnea
1983
Postpartum Perfusion of the Preterm Brain: Relationship to Neurodevelopmental Outcome
Ment L, Scott D, Lange R, Ehrenkranz R, Duncan C, Warshaw J. Postpartum Perfusion of the Preterm Brain: Relationship to Neurodevelopmental Outcome. Child's Brain 1983, 10: 266-272. PMID: 6884128, DOI: 10.1159/000120122.Peer-Reviewed Original ResearchConceptsCerebral blood flow measurementsCBF valuesHigher CBF valuesComputerized tomography scanDays of lifeBlood flow measurementsIntraventricular hemorrhageNeurodevelopmental outcomesPreterm brainPreterm infantsFavorable outcomeTomography scanMental indexDevelopmental assessmentLeft hemisphereOutcomesHemorrhageInfantsPerfusion